Vaxcyte, Inc. PCVX Proceeds from issuance of common stock from follow-on offering, net of issuance costs
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept pcvx:ProceedsFromIssuanceOfCommonStockFromFollowOnOfferingNetOfIssuanceCosts.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s proceeds from issuance of common stock from follow-on offering, net of issuance costs.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s proceeds from issuance of common stock from follow-on offering, net of issuance costs?
- Vaxcyte, Inc. (PCVX) reported proceeds from issuance of common stock from follow-on offering, net of issuance costs of $601.85M in Q1 2026.